Literature DB >> 35597841

Clinical Manifestations and Surgical Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Beyond the NCCN Guidelines.

Heather A Lillemoe1, Roberto N Miranda2, Loretta J Nastoupil3, Mark W Clemens4, Kelly K Hunt5,6.   

Abstract

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon peripheral T cell lymphoma arising in response to textured-surface breast implants. Frequently, BIA-ALCL is indolent and typically presents with peri-implant swelling after breast reconstruction or cosmetic augmentation. However, patients can present with an invasive breast or chest wall mass, palpable lymphadenopathy, or metastatic disease. The current literature is limited regarding surgical recommendations for patients with a more aggressive presentation of BIA-ALCL. This report aims to review the various clinical manifestations of BIA-ALCL, including the more advanced and less frequently encountered presentations, with an emphasis on a multidisciplinary approach, with early involvement of a surgical oncologist.
© 2022. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2022        PMID: 35597841     DOI: 10.1245/s10434-022-11838-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  3 in total

1.  Breast Reconstruction Following Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Authors:  Gregory A Lamaris; Charles E Butler; Anand K Deva; Roberto N Miranda; Kelly K Hunt; Tony Connell; Joan E Lipa; Mark W Clemens
Journal:  Plast Reconstr Surg       Date:  2019-03       Impact factor: 4.730

2.  Characteristics and Treatment of Advanced Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Authors:  Meredith S Collins; Roberto N Miranda; L Jeffrey Medeiros; Marcelo Pinheiro Silva de Meneses; Swaminathan P Iyer; Charles E Butler; Jun Liu; Mark W Clemens
Journal:  Plast Reconstr Surg       Date:  2019-03       Impact factor: 4.730

3.  Breast Implant-associated Anaplastic Large Cell Lymphoma: A Prospective Series of 52 Patients.

Authors:  Sarah E Tevis; Kelly K Hunt; Roberto N Miranda; Caitlin Lange; Chelsea C Pinnix; Swaminathan Iyer; Charles E Butler; Mark W Clemens
Journal:  Ann Surg       Date:  2022-01-01       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.